Compare ImmunityBio Inc. Common Stock (IBRX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Sana Biotechnology Inc — how do they compare? ImmunityBio Inc. Common Stock trades at $10.45 (market cap $10.51B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: ImmunityBio Inc. Common Stock is far larger — about 12.6× Sana Biotechnology Inc's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Sana Biotechnology Inc for 23 Days on average.
| IBRX | SANA | |
|---|---|---|
Market Cap | $10.51B | $836.71M |
Volume | 10,445,785 | 4,507,444 |
Sector | Health | Health |
52-Week High | $11.55 | $5.92 |
52-Week Low | $1.98 | $2.68 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $10.97B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.72, down 1.09% with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with negative revenue, a net loss of $244.17 million in 2025, and negative cash flow. However, analyst sentiment remains positive with 82% buy ratings and recent conference presentations highlighting ongoing research in engineered cell therapies.
The outlook is highly speculative given the pre-revenue stage and substantial losses. Investment opportunity lies in the potential of SANA's biotechnology platform, but risks include cash burn, clinical trial outcomes, and competitive pressures. Wall Street maintains cautious optimism despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
